Clinical Trials Logo

HER-2 Negative Breast Cancer clinical trials

View clinical trials related to HER-2 Negative Breast Cancer.

Filter by:
  • Not yet recruiting  
  • Page 1

NCT ID: NCT05398861 Not yet recruiting - Clinical trials for HER-2 Negative Breast Cancer

Utidelone Combined With Bevacizumab in the Treatment of ≥ 2 Lines of HER-2 Negative Advanced Breast Cancer

Start date: June 1, 2022
Phase: Phase 2
Study type: Interventional

This study is a prospective, single-arm, open-label phase II study to evaluate the efficacy and safety of the combination of Utidelone and bevacizumab regimen in patients with ≥ 2 lines of HER-2 negative advanced breast cancer.